Purpose: The aim of this study was to define the pharmacokinetics of carboplatin in children and use the data to develop a pediatric dose formula. It was anticipated that renal function would be a major determinant of carboplatin disposition and the relationship between carboplatin clearance and glomerular filtration rate (GFR) was examined in detail.
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threefold range and pharmacokinetic studies have been performed in an attempt to explain this variation. A major determinant of carboplatin clearance is renal elimination and, in patients with normal kidney function, 60% to 80% of the dose is excreted in the urine within the first 24 hours.' 0 Two of three published studies have concluded that carboplatin renal clearance takes place at a rate equal to the glomerular filtration rate (GFR) 4 ,1',12 and preclinical data in rats are in agreement." Measurement of pretreatment GFR thus allows the calculation of carboplatin clearance and hence an estimation of the dose of carboplatin required to achieve a given AUC. Calvert et a114 and Egorin et a1 4 have proposed equations, which have been prospectively validated,14-1 6 that calculate the dose of carboplatin required to achieve either a given AUC or degree of thrombocytopenia, respectively. Both dose equations are based on renal function, and the major difference in the approach taken by Egorin et al is the inclusion of a pharmacodynamic end point. In adults, pharmacokinetically based carboplatin dosing has been extended to combination chemotherapy.'1618 The adult carboplatin dose formula developed by Calvert et al 4 is as follows: dose (mg) = target AUC X (GFR [mL/min] + 25), and includes the constant 25 to account for the nonrenal clearance of the drug. Since metabolism or biliary excretion does not play a major role in the elimination of carboplatin, nonrenal clearance is mainly due to reaction with tissue and plasma proteins.lo In discussing the application of pharmacologically based carboplatin therapy to species with smaller body sizes than humans, it was recognized that the nonrenal clearance of carboplatin was likely to be less, due to the lower mass of tissue and plasma protein available for reaction with carboplatin.14 A similar argument applies to pediatric therapy, and the studies described in the present report were performed to develop a pediatric carboplatin-dose formula. At the time these studies were initiated, there were essentially no data available on the pharmacokinetics of carboplatin in children, although a number of reports have since appeared. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, preliminary results with carboplatin had already shown that children with impaired renal function were more likely to experience thrombocytopenia. 23 The objectives of the current study were, therefore, to describe carboplatin pharmacokinetics in children and investigate, in particular, possible relationships between (1) carboplatin renal clearance and GFR, and (2) carboplatin nonrenal clearance and body size. Both of these objectives require the calculation of the renal clearance of carboplatin, which is dependent on complete and accurate urine collections. In practice, it was not possible to obtain satisfactory urine collections from sufficient 2315 patients and it was therefore necessary to adopt an indirect approach in which the relationship between plasma carboplatin clearance and renal function has been studied. In addition, in a subset of patients, the relationship between carboplatin AUC and myelosuppression has been investigated in an attempt to confirm the observation, made in adults, that carboplatin AUC correlates more closely with hematologic toxicity than dose.4-616 Certain aspects of this study have been presented or published in preliminary form. 24 , 25 
PATIENTS AND METHODS

Patients Studied
The patients entered onto this study were all enroled as part of trials conducted under the auspices of the United Kingdom Children's Cancer Study Group. Patients were receiving carboplatin as part of established protocols. The protocols were all approved by the relevant local or regional ethics committees. Informed consent was obtained from the parents or guardians of all patients. Age, sex, body weight, surface area, diagnosis, course, and chemotherapy information for the 22 patients studied are listed in Table 1 .
Carboplatin and Pharmacokinetic Analyses
Carboplatin was administered as a 60-to 90-minute infusion in 5% dextrose through a cannula placed in peripheral vein. Blood samples (3 mL) were taken from a central line before carboplatin, mid infusion, at the end of infusion, and 15, 30, 60, 90, 120, 240, 360, and 480 minutes thereafter. Plasma was prepared within 15 minutes of sample collection by centrifugation at room temperature (10 to 15 minutes) and then plasma ultrafiltrates prepared immediately using Amicon Centrefree micropartition units (Amicon Ltd, Stonehouse, United Kingdom). Plasma ultrafiltrates were stored frozen (< -15 0 C) until analyzed, which was within 2 months of collection.
Carboplatin was measured in plasma ultrafiltrates as free Pt by flameless atomic absorption spectrophotometry." Quality-assurance samples of carboplatin stored frozen at 10 Ag/mL were analyzed with all assays and the intraassay and interassay coefficients of variation were less than 8% and 10%, respectively. The limit of detection of the assay was 0.5 tg/mL carboplatin.
A one-and a two-compartment open pharmacokinetic model with constant-rate intravenous infusion was fitted to each data set. Data were analyzed using the ADAPT (release II) program, kindly made available by Drs D'Argenio and Schumitzky (Biomedical Simulations Resource, University of Southern California, Los Angeles, CA) and data were weighted using the inverse variance of the output error. The results of the one-and two-compartment model analyses were compared using Akaike's information criterion, as recommended by Yamaoka et al, 26 to determine the most appropriate model.
To assist in the interpretation of the volumes of distribution, and to allow comparison of data from patients with widely different body sizes, each result is reported as a proportion (%) of the calculated extracellular fluid (ECF) and total body water (TBW) volume. ECF and TBW were calculated from body weight (BW) using the following equations 27 : ECF (mL) = 583 X BW (kg) 0 . 678 , and TBW (mL) = 843 
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Estimation of Renal Function
Renal function was measured as the GFR from the plasma clearance of chromium 5 l1-edathamil (" 5 Cr-EDTA). 2 8 On all but six occasions, the "SCr-EDTA clearance was measured at the same time as carboplatin pharmacokinetics were studied; in the other patients, "
5 'Cr-EDTA clearance was measured within 1 month of carboplatin therapy during which time no nephrotoxic therapy had been given.
"SCr-EDTA was administered as a bolus dose into a peripheral cannula and three to five blood samples (3 mL) were collected from a central line 60 to 360 minutes after administration. Plasma was prepared immediately as described earlier, and measured aliquots were counted on a Phillips AGA gamma counter (Phillips Ltd, Eindhoven, the Netherlands). The dose of SCr-EDTA administered was calculated by gravimetric measurement and quanititated by comparison with research standards. Corrected plasma radioactivity versus time data were analyzed by fitting a monoexponential equation to the data by nonlinear least-squares regression analysis. The " 5 Cr-EDTA clearance (GFR) is then calculated as follows: s 5 Cr-EDTA clearance = Vd X k.1, where Vd is dose/A (A is the extrapolated concentration at time zero) and k., is the slope of the clearance curve. As described earlier, the 5 1 Cr-EDTA Vd data were also expressed as a percentage of the calculated TBW and ECF volume for each patient. Individual data for the renal function of the patients studied are listed in Table 2 .
Calculation of the Predictive Performance of the Pediatric Carboplatin-Dose Formulas
The ability of the carboplatin-dose formulas to predict the observed carboplatin AUC values was assessed using the approach proposed by Sheiner and Beal. 2 9 The predicted AUC for each patient was expressed as a percentage of the AUC observed in that patient. The bias of each individual prediction was calculated as the predicted AUC (%) minus 100 and the precision as the unsigned result of the predicted AUC (%) minus 100. For the entire patient group (N = 22), the data for predicted AUC, bias, and precision are given as the median, range, and twenty-fifth and seventy-fifth percentiles for each equation evaluated.
Comparison of Carboplatin Pharmacokinetics and Pharmacodynamics
To investigate possible relationships between carboplatin exposure (AUC) and myelosuppression, hematologic data were collected for the period immediately after carboplatin administration until the next course of therapy. Total WBC and platelet counts were measured before and as often as clinically indicated after treatment. Patients were divided into two groups: those receiving only carboplatin or carboplatin plus vincristine, and those receiving other known myelosuppressive drugs (etoposide, high-dose melphalan, or cyclophosphamide). Further analysis of pharmacokinetic/pharmacodynamic relationships was then restricted to patients receiving single-agent carboplatin or carboplatin plus vincristine. A Hill equation was fitted to the data using nonlinear least-squares regression analysis (Fig P, Biosoft, Cambridge, United Kingdom), ie, y = min + (max min)/(1 + [x/x 0 ] -H), where y is the nadir of thrombocyte or leukocyte count, expressed either as the absolute count or as a percentage of the pretreatment count, min and max are the minimum and maximum y values, respectively, x is the carboplatin AUC or dose, x 50 is the carboplatin AUC or dose at the center point of the sigmoid curve, and H is the Hill coefficient dictating the sigmoidicity of the curve. 
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RESULTS
Carboplatin Pharmacokinetics in Children
Carboplatin plasma concentrations, determined as ultrafiltrable Pt, were measured in the plasma of 22 patients following the administration of carboplatin at doses of 200 to 1,000 mg/m 2 . Concentrations of carboplatin increased during the infusion and declined thereafter, approaching the limit of detection (0.5 pg/mL) within 8 to 10 hours in most patients (Fig 1) . The median carboplatin plasma concentration 7 to 9 hours after the start of the infusion was 1.0 gg/mL (range, 0.5 to 5.0 pg/mL). Oneand two-compartment pharmacokinetic models were fitted to the carboplatin concentration versus time data. In 16 of 22 patients, either one-or two-compartment models could be fitted, and in 15 of these patients the two-compartment model described the data more accurately as judged by the Akaike information criteria. In the remaining six patients, a two-compartment model failed to converge meaningfully and data from a one-compartment fit were used. The results of the pharmacokinetic analyses show a wide range of values for absolute and dose-normalized carboplatin AUC, clearance, half-life (t 1 /2), and volume of distribution (Table 3) . Comparison of the car-2317 boplatin clearance data generated for 16 patients by both one-and two-compartment pharmacokinetic analyses (Fig  2) demonstrated that the one-compartment model consistently underestimated the carboplatin AUC, relative to the two-compartment model. In the remainder of the analyses reported, the pharmacokinetic data used are, for the six patients in whom a two-compartment model would not converge, the one-compartment results or that indicated as most appropriate by the Akaike information criterion analysis, ie, two-compartment data in 15 and onecompartment in one of the remaining 16 patients.
The dose-dependency of carboplatin AUC was investigated and, although there was a significant relationship (Fig 3) , there was extremely wide variation. The possible contribution of differences in renal function, and hence carboplatin renal clearance, was investigated.
Relationship Between Carboplatin Pharmacokinetics and Renal Function
The absolute total plasma clearance of carboplatin was found to be significantly related to absolute (mL/min) " 5 t Cr-EDTA clearance (Fig 4A) . However, when both carboplatin and 51
Cr-EDTA clearances were normalized for surface area (mL/min/1.73 m2), the relationship was much weaker (Fig 4B) . Notably, the extrapolated y-axis intercept for the surface area-adjusted clearances was very high (82 mL/min/1.73 m2), and the variation in the data resulted in wide confidence limits for this value (95% confidence limits, 39 to 125 mL/min/1.73 m 2 ).
Derivation of a Pediatric Carboplatin-Dose Formula
The data generated on the relationship between carboplatin and " 5 Cr-EDTA clearance (Fig 4) were too vari- able to allow the derivation of a pediatric dose formula using the same approach used to derive the adult dose formula.14 Hence, an alternative method was investigated.
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In the adult dose formula, ie, dose (mg) = target AUC X (GFR [ 30 Thus, the mean nonrenal clearance of carboplatin (25 mL/min) is equivalent to 0.36 mL/min/ kg. Applying this latter factor for nonrenal clearance, the formula for calculating carboplatin total plasma clearance becomes carboplatin clearance (mL/min) = GFR (mL/ min) + 0.36 X BW (kg). Using this body size-adjusted formula for estimating carboplatin clearance, the expected carboplatin AUC values were calculated for the pediatric patients investigated in the present study (equation 2, Table 4 ). The BW-adjusted formula, in contrast to the nonadjusted adult formula (equation 1, Table 4 ), accurately predicted the observed AUC values without bias. On the basis of these data, the following provisional pediatric dose formula is proposed: dose (mg) = target AUC X (GFR (mL/min) + [0.36 X BW (kg)]).
It should be noted that in certain children an unrealistically high 5 "Cr-EDTA clearance was observed, for ex- Table 2 ).
The reason for high values was found to be the large volumes of S"Cr-EDTA distribution observed in some children. Thus, as a percentage of calculated TBW, "SCr-EDTA volumes of distribution as large as 169% of TBW were recorded (Table 2 ). In contrast, the " 5 Cr-EDTA t,/2 values were less variable and these data support the clinical impression that "5Cr-EDTA t 1 , 2 is a more consistent measure of renal function than " 5 Cr-EDTA clearance, due to the error introduced by the inclusion of the volume of distribution term. Thus, alternative dose formulas were developed in which GFR is not the reported value, but a GFR derived from the measured " 5 Cr-EDTA t 11 /2 and a calculated 5 t Cr-EDTA volume of distribution.
Two approaches were taken to estimate the S'Cr-EDTA volume of distribution. The first used the published volume, namely, 175% of the inulin or ECF volume. These two 5'Cr-EDTA tl/2-based equations were also used to calculate expected carboplatin AUC values in the pediatric patients investigated in the present study. As shown in Table 4 (equations 3 and 4), both equations is not as marked as in the case of the adult dose formula, in which the AUC was underpredicted by a median of 41%. In summary, the carboplatin clearance formulas that scale nonrenal clearance on the basis of body size (Table  4 , equations 2 through 4) are both more precise and less biased than the adult formula (Table 4, When a reliable GFR estimation is not available, the use of a formula based on the tl/ 2 of 51Cr-EDTA is proposed and, due to slightly reduced bias and similar precision (Table 4, 
Relationships Between Carboplatin Pharmacokinetics and Pharmacodynamics
To use a carboplatin-dose formula that aims to achieve reproducible drug exposure, it is necessary to identify target AUC values. To identify target AUC values, AUC/ toxicity and AUC/response relationships must be defined, both of which will be influenced by concurrent antineoplastic therapy, prior treatment, and disease state. In the present study, the wide range of disease types and prior therapies made investigations of AUC/response relationships impractical. However, a subset of patients (n = 8) received either only carboplatin or carboplatin in combination with vincristine alone, a relatively nonmyelosuppressive drug. In addition, two further pediatric patients were identified for whom carboplatin toxicity and pharmacokinetic data, but not " 5 Cr-EDTA clearance results, were available. These latter two patients also received only single-agent carboplatin. For this total of 10 patients, there was a significant sigmoidal relationship between thrombocytopenia and AUC, when the thrombocyte nadir was expressed as a percentage of the pretreatment count (Fig 5A) . In contrast, there was no relationship between thrombocytopenia and carboplatin dose (Fig 5B) . There was also no relationship between absolute nadir platelet count or leucopenia (absolute to percentage nadir) and either carboplatin dose or AUC.
DISCUSSION
The primary objectives of the studies described here were to define the pharmacokinetics of carboplatin in children and use the data to develop a pediatric dose formula. Qualitatively, the pharmacokinetics of carboplatin in children were similar to those in adults," 0 and this agrees with other pediatric carboplatin pharmacokinetic data recently published. A notable feature of the pharmacokinetics of carboplatin in children is the variability in AUC achieved even when the administered dose is corrected for surface area ( Table 3 ). The threefold variation seen in the present study agrees closely with that observed by Madden et al, 22 although Riccardi et al2 have reported more consistent results. Although it was possible to show a weak correlation between dose administered and AUC (Fig 3) , the variability encountered argues strongly against relying on sur- 5 Cr-EDTA t 1 /2 and a S t Cr-EDTA volume of distribution derived from more recent (unpublished) adult data. Using these three clearance equations, expected carboplatin AUC values were calculated for the children investigated in the current study (Table 4) . For the two equations recommended (equations 2 and 4, Table 4), the median bias for the predicted AUC was less than ± 10% and the median precision was less than 30%. It should be stressed that the equations used to calculate the expected carboplatin clearances were based solely on the adult data .
• .and did not use any of the pediatric data gained in the 0 5 10 15 20 present study.
Carboplatin AUC (mg/ml.min) If the nonrenal clearance of carboplatin is solely body size-dependent, and the factor of 0.36 mL/min/kg is correct, it should be possible to predict carboplatin clearances B in species other than humans. In Table 5 , this has been done for mice, rats, and dogs, the only species for which observed carboplatin clearances are available. 13, 32 33 In the * case of the dog, it was necessary to estimate 34 the GFR from the BW of the animals used to study carboplatin pharmacokinetics, as GFR measurements were not obtained. 33 However, the value obtained is well within the Croduced by fitting the Hill equation to the data, R 2 = .56 EDTA clearance, and hence GFR, suggested that estimation of the "sCr-EDTA volume of distribution may ,a-based dosing alone for carboplatin therapy in have been particularly inaccurate ( Table 2 ). In a group of i. A similar conclusion was reached by Madden ovarian cancer patients (S.G. Aswad and D.R. Newell, who were unable to distinguish between the AUC unpublished results), intrapatient variation in the volume ed by 400 and 700 mg/m 2 of carboplatin. of distribution was twofold greater than the variation in In view of the large body of adult data, " differences in renal clearance are likely to be responsible for the wide variation in dose-normalized carboplatin AUC values. Although initial attempts were made to obtain accurate urine collections, and hence define the renal and nonrenal clearance of carboplatin in children, this proved impractical due to the young age of a number of the children studied. Instead, the adult dose equation was modified by using the factor 0.36 mL/min/kg BW in place of 25 mL/ min to account for the nonrenal clearance of carboplatin. This factor for the nonrenal clearance of carboplatin was then incorporated into three carboplatin clearance formulas. These used the reported GFR, the 5 'Cr-EDTA t1/ 2 , . 33 tObserved inulin clearances in mice35 and rats. 1 3 tCarboplatin clearance calculated as GFR calculated + 0.36 X BW (kg). §Observed carboplatin clearances in mice, 3 ' rats,' 3 and dogs. 
